Last reviewed · How we verify
14C-labelled GFT505 120 mg — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
14C-labelled GFT505 120 mg (14C-labelled GFT505 120 mg) — Genfit.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| 14C-labelled GFT505 120 mg TARGET | 14C-labelled GFT505 120 mg | Genfit | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- 14C-labelled GFT505 120 mg CI watch — RSS
- 14C-labelled GFT505 120 mg CI watch — Atom
- 14C-labelled GFT505 120 mg CI watch — JSON
- 14C-labelled GFT505 120 mg alone — RSS
Cite this brief
Drug Landscape (2026). 14C-labelled GFT505 120 mg — Competitive Intelligence Brief. https://druglandscape.com/ci/14c-labelled-gft505-120-mg. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab